Enhancing Parasympathetic Activity with Pyridostigmine
Corresponding Organization :
Other organizations : Ministry of Health of the Russian Federation, Institute of Experimental Medicine, Federal Almazov North-West Medical Research Centre, First Pavlov State Medical University of St. Petersburg
Variable analysis
- Pyridostigmine (cholinesterase inhibitor) at a daily dose of 40 mg/kg
- Total parasympathetic activity
- Administration of pyridostigmine via intragastric route using a commercially available polypropylene feeding tube
- Duration of treatment: 6 weeks
- No positive or negative controls were explicitly mentioned in the provided information.
Annotations
Based on most similar protocols
As authors may omit details in methods from publication, our AI will look for missing critical information across the 5 most similar protocols.
About PubCompare
Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.
We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.
However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.
Ready to get started?
Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required
Revolutionizing how scientists
search and build protocols!